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The interactions of -conopeptide MrIA with the hu-
man norepinephrine transporter (hNET) were investi-
gated by determining the effects of hNET point muta-
tions on the inhibitory potency of MrIA. The mutants
were produced by site-directed mutagenesis and ex-
pressed in COS-7 cells. The potency of MrIA was greater
for inhibition of uptake by hNET of [3H]norepinephrine
(Ki 1.89 M) than [
3H]dopamine (Ki 4.33 M), and the
human dopamine transporter and serotonin transporter
were not inhibited by MrIA (to 7 M). Of 18 mutations
where hNET amino acid residues were exchanged with
those of the human dopamine transporter, MrIA had
increased potency for inhibition of [3H]norepinephrine
uptake for three mutations (in predicted extracellular
loops 3 and 4 and transmembrane domain (TMD) 8) and
decreased potency for one mutation (in TMD6 and intra-
cellular loop (IL) 3). Of the 12 additional mutations in
TMDs 2, 4, 5, and 11 and IL1, three mutations (in TMD2
and IL1) had reduced MrIA inhibitory potency. All of the
other mutations tested had no influence on MrIA po-
tency. A comparison of the results with previous data for
desipramine and cocaine inhibition of norepinephrine
uptake by the mutant hNETs reveals that MrIA binding
to hNET occurs at a site that is distinct from but over-
laps with the binding sites for tricyclic antidepressants
and cocaine.
The norepinephrine transporter (NET)1 terminates neuro-
transmission by rapid and specific uptake of norepinephrine
into presynaptic nerve terminals (for review see Refs. 1 and 2).
Tricyclic antidepressants are competitive inhibitors of the
NET, and this property contributes to their efficacy in the
treatment of conditions such as depression (3). Studies on chi-
meras between the human NET (hNET) and the highly homol-
ogous dopamine transporter (DAT) have provided evidence
that the sites involved in the selective inhibition by the tricyclic
antidepressants of NET relative to DAT involves the region
spanning transmembrane domains (TMDs) 6–8 of the putative
12 TMD topology predicted for these transporters (4, 5). More
recently, interactions of tricyclic antidepressants with the NET
have been further investigated in a study in which point mu-
tations were introduced into the region spanning TMDs 6–8 of
hNET by replacing amino acids in hNET with those found in
human DAT (hDAT) (6). The latter study (6) identified that key
hNET amino acid residues responsible for the inhibitory effects
of tricyclic antidepressants are contained within TMDs 6, 7,
and 8 and not in the adjacent intracellular loops (ILs) or extra-
cellular loops (ELs) (6). It was also shown that the identified
sites are not important determinants of substrate transport (6).
However, TMDs 6–8 are not the only regions important for
determining tricyclic antidepressant interactions with the
NET. Point mutations of other amino acids in TMDs 2 and 5
and in the first IL of the hNET have also been shown to cause
reductions in the affinities for the NET of tricyclic antidepres-
sants, and in some cases, of cocaine (7–9).
Conotoxins are highly structured venom peptides that have
proved to be valuable tools for defining the architecture of
membrane-bound proteins including sodium channels (10), cal-
cium channels (11), and potassium channels (12). Recently, the
-conopeptide MrIA, isolated from Conus marmoreus, has been
identified to be a non-competitive inhibitor of [3H]norepineph-
rine uptake by the NET (13) but a competitive inhibitor of
[3H]mazindol and [3H]nisoxetine binding to both rat and hu-
man NET (26). This activity contrasts with the competitive
inhibition of NET transport of norepinephrine by tricyclic an-
tidepressants. In the present study, we investigate MrIA bind-
ing to hNET by examining the influence on the inhibitory
potency of MrIA of point mutations in regions that have been
proposed to be involved in determining the affinity of the tri-
cyclic antidepressants for the hNET (see Fig. 1) (6). The results
of this study have implications for NET structure/function re-
lationships, which are presently poorly defined.
MATERIALS AND METHODS
Chemicals—()-[ring-2,5,6-3H]Norepinephrine (NET-678, 1917 Bq/
pmol), [ring-2,5,6-3H]dopamine (NET-673, 2190 Bq/pmol), and [1,2-
3H(N)]5-hydroxytryptamine creatinine sulfate ([3H]5-HT, NET-498,
888 Bq/pmol) were obtained from PerkinElmer Life Sciences. The
-conopeptide MrIA (supplied by Xenome Ltd, Brisbane, Queensland,
Australia) was obtained by solid phase peptide synthesis and purified
by reversed-phase high pressure liquid chromatography to95% purity
as previously described (13). The drugs used in the study were as
follows:1-{2-[bis(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)pipe-
razine dihydrochloride (GBR12909, Research Biochemicals Incorpo-
rated, Natick, MA); 3,4-dihydroxy-2-methylpropiophenone (U-0521,
donated by Pharmacia and Upjohn, Kalamazoo, MI); dopamine hydro-
chloride (Sigma); 5-HT creatinine sulfate (Sigma); nisoxetine hydro-
chloride (donated by Eli Lilly and Company, Indianapolis, IN), norepi-
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nephrine bipartite (Sigma), pargyline hydrochloride (Sigma), and
paroxetine hydrochloride (donated by GlaxoSmithKline, Uxbridge,
Middlesex, United Kingdom).
Stock solutions of 2.5 mM -MrIA (MrIA-NH2) were prepared in
water, quantitated by amino acid analysis, and stored at 20 °C in
polypropylene tubes. Stock solutions of norepinephrine (10 mM), 5-HT
(10 mM), and dopamine (100 mM) were prepared in 10 mM HCl, and
stock solutions of U-0521 (1 mM), GBR12909 (100 M), and all of the
other drugs (10 mM) were prepared in water. All of the dilutions were
prepared on the day of the experiment in Krebs/HEPES buffer (compo-
sition in mM: NaCl 125, KCl 4.8, MgSO4 1.2, KH2PO4 1.2, CaCl2 1.3,
HEPES 25, glucose 5.55, ascorbic acid 1.02, U-0521 0.005 (to inhibit
catechol-O-methyltransferase), and pargyline 0.001 (to inhibit monoa-
mine oxidase), pH 7.4) containing 0.1% bovine serum albumin.
Cell Culture and Transfection—COS-7 (SV40-transformed African
Green monkey kidney cells, American Type Culture Collection,
Manassas, VA) were grown at 37 °C in a 5% CO2 humidified atmo-
sphere on standard plastic cultureware in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% fetal calf serum (Invitro-
gen) and 100 units/ml penicillin and 100 g/ml streptomycin (Invitro-
gen) to obtain complete medium. COS-7 cells were subcultured onto
12-well culture plates. The cells were transiently transfected with the
cDNA of hNET (donated by Professor S. Amara, Vollum Institute,
Portland, OR), hDAT (donated by Professor M. Caron, Duke University,
Durham, NC), human serotonin transporter (hSERT, donated by Pro-
fessor R. Blakely, Vanderbilt University School of Medicine, Nashville,
TN), or mutant hNET using LipofectAMINE (Invitrogen) as described
previously (15). The mutant hNETs were obtained by site-directed
mutagenesis in previous studies in our laboratories (6–9, 16). The
experiments were performed 48 h following the transfection.
Uptake Assays—Culture medium was removed from the transiently
transfected COS-7 cells, and they were then washed twice with 1 ml of
Krebs/HEPES buffer containing 0.1% bovine serum albumin at 37 °C.
The cells were incubated for 60 min at 37 °C with 0.5 ml of Krebs/
HEPES buffer containing 0.1% bovine serum albumin in the absence or
presence of 0.07–21.3 M MrIA and inhibitors to determine nonspecific
uptake (1 or 10 M nisoxetine for wild type and mutant hNETs, 1 M
GBR12909 for hDAT, or 1 M paroxetine for hSERT). [3H]Norepineph-
rine, [3H]dopamine, or [3H]5-HT (10 nM) was then added for 2 min. The
cells were washed three times with Krebs/HEPES buffer at 0 °C and
lysed (750 l of 0.1% Triton X-100 in 10 mM Tris-HCl, pH 7.5, at 37 °C
for 60 min). Determination of the protein content by the Lowry method
(17) was carried out on duplicate samples of 75 l of the lysate, and the
3H content of 500 l of the lysate was determined by the addition of 1.5
ml of Starscint scintillation medium (Packard, Melbourne, Victoria,
Australia) and liquid scintillation counting. Samples (50 l) of the [3H]
solutions were taken to determine the specific activity of the incubation
solutions.
Data Analysis—[3H]Amine uptake was calculated using the results
of the Lowry protein determination and the liquid scintillation count-
ing. Specific uptake of [3H]amine was calculated as the difference be-
tween uptake in the absence (total uptake) and presence (nonspecific
uptake) of nisoxetine, GBR12909, or paroxetine as appropriate. IC50
values for inhibition of [3H]norepinephrine or [3H]dopamine uptake by
MrIA and the Hill slopes for the curves were calculated by non-linear
regression analyses of data for percentage inhibition of specific
[3H]norepinephrine or [3H]dopamine uptake versus log drug concentra-
tion for each individual experiment according to a sigmoidal model
(Prism 3, GraphPad Software, San Diego, CA). The IC50 value for MrIA
is equal to its Ki value (18), because MrIA is a non-competitive inhibitor
of norepinephrine uptake by hNET (13). Arithmetic means  S.E. or
geometric means and 95% confidence limits of uptake data or kinetic
parameters were calculated as indicated under “Results.” Hill slopes
were compared with a slope of 1.0 using the Student’s t test (Instat 3,
GraphPad). The significance of differences between values was deter-
mined by one factor analysis of variance (ANOVA, repeated measures
FIG. 1. Topological map of the hNET and the mutants used in this study. Extracellular amino acid residues are above the horizontal lines
representing the cell membrane, and those below are intracellular residues with TMDs 1–12 between the lines. The letters in the circles show the
amino acid sequence (by one-letter code) of the hNET (25). The N and C termini are shown as NH2 and COOH, respectively. The numbers shown
(where possible) are the predicted amino acid positions of the first and last residues of each IL and EL based on hydrophobicity plots and sequence
alignment of the monoamine transporters (14, 25). Mutants investigated in this study are indicated by filled symbols and the accompanying labels.
Mutations that resulted in an increase (Œ) or decrease () in MrIA potency for inhibition of hNET are indicated (see also Table I).
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where appropriate) followed by Dunnett’s multiple comparison tests
(Prism 3) on absolute or log data or by Student’s t test as indicated
under “Results.”
RESULTS
Selective Inhibition of hNET by MrlA—The uptake of
[3H]norepinephrine and [3H]dopamine by hNET was deter-
mined in the presence of increasing concentrations of MrIA
(Fig. 2). The inhibition curves had Hill slopes that were not
significantly different from 1. The Ki value of MrIA obtained
from these data with norepinephrine as substrate (1.89 M,
95% confidence limits: 1.76, 2.02 M, n  5) was significantly
less (p 0.001) than that with dopamine as substrate (4.33 M,
95% confidence limits: 3.55, 5.43 M, n  4). MrIA, over the
concentration range that caused up to 80% inhibition of
[3H]norepinephrine uptake by hNET, had no effect on [3H]do-
pamine uptake by hDAT or on [3H]5-HT uptake by hSERT (Fig.
2), confirming the lack of effect of MrIA at these related mono-
amine transporters.
Influence of hNET Mutants on Inhibition of Norepinephrine
Uptake by MrIA—COS-7 cells transiently expressing wild type
hNET or hNET mutants were screened for inhibition of
[3H]norepinephrine uptake by MrIA in three series of experi-
ments. In view of the highly selective inhibition of hNET com-
pared with hDAT by MrIA (Ref. 13 and this study), the first two
series of experiments investigated the effects of mutations that
resulted in amino acid exchanges of residues of the hNET to
those of the hDAT in ELs 3 and 4, IL 3, and TMDs 5–8 (Fig. 3,
A and B). Inhibition by MrIA was significantly greater than
that of hNET for K303C (EL 3), E377G-E382D-A384P (EL 4),
and S399P (TMD 8), less than that of hNET for F316C-D336T
(mutations in TMD 6 and IL 3), and was the same as hNET for
the other 13 mutations in these regions including the F316C
and D336T point mutants and the double mutant S399P-
G400L (Fig. 3). In the third series of experiments using a
different batch of MrIA, the effects of point mutations to ala-
nine or other amino acids in TMDs 2, 4, 5, and 11 and in IL 1
on the inhibition of [3H]norepinephrine uptake by MrIA were
investigated. These studies indicated that there was less inhi-
bition of the mutant than that of wild type hNET by MrIA for
L114A and L114S in TMD 2 and G123A in IL 1 (Fig. 4). No
significant differences from hNET were observed for the re-
maining 10 mutants examined (Fig. 4).
Determination of Ki Values of MrIA for hNET Mutants—The
effects of a range of MrIA concentrations on [3H]norepineph-
rine uptake were determined for hNET and five of the mutants,
which showed significantly different inhibition by MrIA from
that of hNET (Figs. 3A and 4). Ki values of MrIA were deter-
mined from the results shown in Fig. 5 for hNET and the five
mutants (Table I), assuming that MrIA is a non-competitive
inhibitor of norepinephrine uptake by hNET (13). The Hill
slopes of the inhibition curves were not significantly different
from 1 except for K303C, which showed a small increase. Ki
values of MrIA are also shown in Table I for the two mutants
that showed significantly different inhibition by MrIA com-
pared with hNET in Fig. 3B, and these values were calculated
from the data in Fig. 3B, assuming a Hill slope of 1. The Ki
values of MrIA for inhibition of the seven mutant NETs all
FIG. 2. Inhibition of hNET, hDAT, and hSERT by MrIA in
COS-7 cells transiently expressing the transporters. Specific up-
take of [3H]amine (10 nM, 37 °C, 2 min) was determined as the differ-
ence between uptakes in the absence and presence of 10 M nisoxetine
for hNET, 1 M GBR12909 for hDAT, or 1 M paroxetine for hSERT in
the absence or presence of the appropriate concentration of MrIA. The
values of percentage inhibition of specific [3H]amine uptake by MrIA
are shown as arithmetic means  S.E. for hNET with [3H]norepineph-
rine (, n  5) or [3H]dopamine (E, n  4) as substrate, hDAT with
[3H]dopamine as substrate (f, n  2), and hSERT with [3H]5-HT as
substrate (Œ, n  3) versus concentration of MrIA (on a log scale).
Curves for hNET were obtained by non-linear regression analysis using
a sigmoidal model.
FIG. 3. Inhibition of [3H]norepi-
nephrine uptake by MrIA in COS-7
cells transiently expressing hNET or
hNET with point mutations in ELs 3
or 4, IL 3, or TMDs 5–8. Specific uptake
of [3H]norepinephrine (10 nM, 37 °C, 2
min) was determined as the difference be-
tween uptakes in the absence and pres-
ence of 10 M nisoxetine. The values for
percentage inhibition of specific norepi-
nephrine uptake by MrIA (1.78 M for
panel A and 2.13 M for panel B) are
shown as arithmetic means  S.E. (n 
3). The horizontal lines show the inhibi-
tion of hNET by MrIA. The data were
analyzed by repeated measures one factor
ANOVA (p  0.001 in A and p  0.01 for
B) followed by Dunnett’s multiple com-
parison tests compared with hNET (*, p
0.05; ***, p  0.001).
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differed significantly from those for the inhibition of hNET
with three mutations in ELs 3 and 4 and TMD 8, causing an
increase in MrIA potency, and four mutations in IL 1, TMD 2,
and TMD 6  IL 3, causing a decrease in MrIA potency (Table
I). In Table II, the effects of the point mutations of hNET on the
inhibitory potency of MrIA are compared with their effects on
the inhibitory potencies of desipramine (DMI) and cocaine and
the apparent affinity of dopamine determined from previous
studies in our laboratories.
DISCUSSION
The -conopeptide MrIA is a non-competitive inhibitor of
norepinephrine uptake by NET with greater than 1000-fold
selectivity for inhibition of NET compared with DAT and SERT
(this study and Ref. 13). In contrast to cocaine and tricyclic
antidepressants such as DMI (6, 15), MrIA was more potent as
an inhibitor of norepinephrine uptake than as an inhibitor of
dopamine uptake by hNET. It appears that the potency of MrIA
inhibition of hNET is influenced by the nature of the amine
being transported. One possible explanation of these results
could be that the binding of MrIA is linked to NET gating,
which is more efficiently modulated by norepinephrine than
dopamine as indicated, for example, by the higher maximal
rate of transport of norepinephrine than dopamine (7, 19, 20).
However, the data from the current study do not provide con-
clusive evidence for this proposal.
To identify where MrIA acts on NET, we examined the effect
of exchanging residues that differ between NET and DAT on
the potency of MrIA inhibition. Because MrIA is a non-compet-
itive inhibitor of norepinephrine uptake by hNET (13) but a
competitive inhibitor of tricyclic antidepressant binding to the
NET (26), we specifically examined whether MrIA and tricyclic
antidepressant binding sites overlapped by determining the
influence on MrIA potency of substituting amino acid residues
in TMDs 5–8 of hNET with their corresponding residues from
hDAT. This region of the NET has been recognized in NET/
DAT chimera studies as being responsible for the translocation
of substrates and cosubstrates (4, 5, 20, 21), and specific resi-
dues in TMDs 6 and 7 have recently been identified to contrib-
ute to the binding of tricyclic antidepressants (6). The simplest
explanation of the competitive inhibition of norepinephrine
uptake by tricyclic antidepressants but non-competitive inhi-
bition by MrIA is that the MrIA binding site may be partially
overlapping the tricyclic antidepressant binding site but sepa-
rate from the site of interaction of substrates with the NET.
The separation of conotoxin, substrate, and tricyclic antide-
pressant binding sites on the NET is further supported by the
finding that several hNET mutations, including G117A,
G123A, F316C-D336T, and the mutations of T268 and Y271,
resulted in differing effects on the apparent affinities of the
conotoxin, MrIA, the tricyclic antidepressant, DMI, and the
substrate, dopamine (Table II).
A comparison of the influence of 30 mutations of the hNET
on MrIA, DMI, and cocaine potencies and on the apparent
affinity of dopamine is given in Table II. Of the mutants exam-
ined, 23 had no effect on MrIA potency. 11 of these mutants
also had no influence on DMI or cocaine potency, and 16 had no
influence on the apparent affinity of dopamine, including 12
mutants that did not change the potencies of any of the tested
compounds. Of the remaining mutants, only the L114A and
L114S mutants in TMD 2 concomitantly reduced (3–10-fold)
the potencies of MrIA, DMI, and cocaine but these mutations
caused increases in the apparent affinity of dopamine. In con-
FIG. 4. Inhibition of [3H]norepinephrine uptake by MrIA in
COS-7 cells transiently expressing hNET or hNET with point
mutations in IL 1 or TMDs 2, 4, 5, or 11. Specific uptake of [3H]nore-
pinephrine (10 nM, 37 °C, 2 min) was determined as the difference
between uptakes in the absence and presence of 1 M nisoxetine. The
values for percentage inhibition of specific norepinephrine uptake by
0.355 M MrIA are shown as arithmetic means  S.E. (n  3). The
horizontal line shows the inhibition of hNET by MrIA. The data were
analyzed by repeated measures one factor ANOVA (p  0.001) followed
by Dunnett’s multiple comparison tests compared with hNET (*, p 
0.05).
FIG. 5. Inhibition of [3H]norepinephrine uptake by MrIA in
COS-7 cells transiently expressing hNET or hNET with point
mutations that caused marked changes in inhibition by MrIA.
Specific uptake of [3H]norepinephrine (10 nM, 37 °C, 2 min) was deter-
mined as the difference between uptakes in the absence and presence of
10 M nisoxetine and was determined in the absence or presence of the
appropriate concentration of MrIA. The values of percentage inhibition
of specific [3H]norepinephrine uptake by MrIA are shown as arithmetic
means  S.E. (n  3–5) for hNET (), K303C (), S399P (‚), G123A
(f), L114A (), and L114S (Œ) versus concentration of MrIA (on a log
scale). Curves were obtained by non-linear regression analysis using a
sigmoidal model, and IC50 values were obtained from analysis of the
data for individual experiments.
TABLE I
Ki values of MrIA for inhibition of norepinephrine uptake in COS-7
cells expressing wild type and mutant hNETs
Ki values (geometric means with 95% confidence limits) and Hill
slopes (arithmetic means  S.E.) were calculated by non-linear regres-
sion analysis of the data in Fig. 5. For the remaining two mutants, Ki
values were obtained from the data in Fig. 3B assuming a Hill slope of
1. Ki values of MrIA are equal to its IC50 values (18) because MrIA is a
non-competitive inhibitor of noradrenaline uptake by the NET (13).
hNET mutant n Ki of MrIA Hill slope
M
hNET 8 1.72 (1.51, 1.95) 0.99  0.04
E377G-E382D-A384P 3 0.77 (0.39, 1.52)a
K303C 3 0.90 (0.72, 1.11)a 1.21  0.03b
S399P 3 0.96 (0.87, 1.06)a 1.01  0.13
F316C-D336T 3 2.82 (1.15, 6.92)a
G123A 3 3.47 (2.23, 5.40)a 1.03  0.19
L114A 3 5.05 (3.11, 8.21)a 0.96  0.08
L114S 3 16.7 (16.0, 17.5)a 1.24  0.10
a p  0.001, for comparison of log Ki values with the hNET control
(one factor ANOVA, p  0.001 followed by Dunnett’s multiple compar-
ison tests).
b p  0.05, for comparison of Hill slope with 1 (Student’s t test).
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trast, the G123A mutation in IL 1 caused a 2–3-fold reduction
in MrIA and cocaine potencies but had no effect on DMI po-
tency and caused a similar increase in apparent affinity of
dopamine. The double mutant F316C-D336T in TMD 6/IL 3
caused a small (1.6-fold) reduction in MrIA potency but a more
marked reduction in DMI potency and no effect on that of
cocaine or on the apparent affinity of dopamine. Surprisingly,
three other mutations (K303C in EL 3, S399P in TMD 8, and
E377G-E382D-A384P in EL 4) enhanced MrIA potency by 2-
fold without having any effect on DMI or cocaine potency or
dopamine apparent affinity. The five TMD 5 mutations were of
particular interest in that they had no influence on MrIA
potency, reduced both DMI and cocaine potencies, and in-
creased the apparent affinity of dopamine compared with
hNET. These results confirm previous findings that the bind-
ing sites for substrates, DMI, and cocaine are overlapping but
not identical (6, 7, 16) and support the idea that the MrIA
binding sites are also not identical to but show some overlap
with those for NET substrates and inhibitors.
The non-competitive inhibition of norepinephrine transport
by MrIA, which is a polar and positively charged peptide,
indicates that MrIA binds to an allosteric binding site located
in the extracellular region of the NET and that this binding
does not change the affinity of norepinephrine for the NET but
reduces its rate of translocation from outside to inside. Two
mutants in EL 3 and EL 4 (K303C and E377G-E382D-A384,
respectively) enhanced MrIA binding, suggesting that MrIA
binding spans these loops which are within the region between
TMD 6 and TMD 8 proposed to be involved in the substrate
translocation process (20). Two models have been proposed to
explain substrate transport by Na-dependent monoamine
transporters such as the NET. In the “alternating model”,
binding of norepinephrine (and the cosubstrates Na and Cl)
leads to a conformational change of the NET enabling release of
norepinephrine (and the cosubstrates) from the transporter on
the inside of the membrane. The empty carrier then turns
outward to complete the transport cycle (see Refs. 22 and 23).
This model implies that the NET forms a type of channel that
is closed on one side and is open on the other side. Recently, an
open-channel model for coupled substrate and Na transport
by the Na-dependent monoamine neurotransmitter trans-
porters, such as NET and SERT, has been proposed based on
the assumption that the transporters form a long narrow pore
enabling translocation analogous to single-file diffusion (24). If
EL 3 and EL 4 form part of the extracellular section of such a
pore, non-competitive inhibition of norepinephrine transport
by MrIA could be explained if MrIA occludes the pore of the
channel. Leucine 114 in TMD 2, close to its junction with IL 1,
also influences MrIA (and DMI and cocaine) potency for inhi-
bition of hNET. If pore occlusion is indeed the mechanism by
which MrIA inhibits substrate transport by hNET, the pore
needs to be of sufficient size to allow MrIA to enter the pore at
a sufficient distance to be influenced by amino acid residues in
the intracellular part of this TMD.
The results of this study show that MrIA interacts with
hNET mostly at residues that differ from those where DMI and
TABLE II
Comparison of the inhibitory potencies of MrIA, DMI, and cocaine and the apparent affinity of dopamine for NET mutants examined
Changes in the potencies of MrIA, DMI, and cocaine for inhibition of norepinephrine uptake and in the apparent affinity of dopamine for each
mutant compared with hNET are shown. 0  no significant change. Significant changes are shown as x-fold change in Ki or Km with2  decrease
in potency (increase in Ki or Km) and 1  increase in potency (decrease in Ki or Km).
Mutant Location 	MrIA potency 	DMI potency 	Cocainepotency
	Dopamine
apparent
affinity
-fold -fold -fold -fold
E113Q TMD2 0 0a 0a 0a
L114A TMD2 2.9 2 2.8 2b 5.1 2b 1.9 1b
L114S TMD2 9.7 2 5.9 2b 8.9 2b 2.8 1b
G117A TMD2 0 5.5 2c 0c 1.5 1c
R121G IL1 0 0c 0c 1.3 1c
G123A IL1 2.0 2 0c 2.7 2c 3.2 1c
Y249A TMD4 0 0d 0d 0d
T268A TMD5 0 2.1 2e 2.2 2e 6.8-fold 1e
T268H TMD5 0 2.8 2e 1.9 2e 7.8-fold 1e
Y271A TMD5 0 1.7 2d 3.3 2d 1.9-fold 1e
Y271F TMD5 0 2.4 2d 2.1 2d 3.1-fold 1e
Y271H TMD5 0 1.7 2d 2.5 2d 1.7-fold 1e
H280R TMD5 0 0f 0f 0f
K303C EL3 2.0 1 0f 0f 0f
F316C TMD6 0 6.5 2f 2.2 1f 0f
A330S IL3 0 0f 0f 0f
D336T IL3 0 0f 0f 0f
I364F TMD7 0 0f 0f 0f
N375P EL4 0 0f 0f 0f
S399P TMD8 1.8 1 0f 0f 0f
G400L TMD8 0 3.2 2f 0f 0f
F403A TMD8 0 0f 0f 0f
A414T TMD8 0 0f 0f 0f
F531Y TMD11 0 0d Small 2d 0d
F316C-D336T TMD6/IL3 1.6 2 28 2f 0f 0f
S399P-G400L TMD8 0 2400 2f 0f 0f
S288I-N289D-N292R EL3 0 0f 0f 0f
F316C-V356S-G400L TMD6/7/8 0 36 2f 0f 0f
E377G-E382D-A384P EL4 2.2 1 0f 0f 0f
H370Q-E371K-K373S-E377G EL4 0 0f 1.9 1f 0f
a Ref. 8.
b F. A. Paczkowski and L. J. Bryan-Lluka, unpublished data.
c Ref. 16.
d Ref. 7.
e Ref. 9.
f Ref. 6.
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cocaine bind. Thus, the competitive inhibition of tricyclic anti-
depressant binding by MrIA (26) most probably occurs via
steric overlap with DMI and MrIA interacting at distinct sites
on the NET, but the binding of DMI precludes MrIA access, and
vice versa. That MrIA and tricyclic antidepressants have sep-
arate binding sites is not unexpected given the differences in
the mode of action of these two classes of inhibitor for inhibition
of noradrenaline uptake (non-competitive and competitive, re-
spectively). Additional interactions remain to be identified to
explain fully how MrIA binds to the NET without interacting at
DAT. Additional interacting residues are also likely to account
for a 25-fold selectivity gap between the affinities of DMI for
NET and DAT, presently unexplained by the data obtained
with NET mutants (6). Identification of these interacting resi-
dues may reveal additional regions of overlap among MrIA,
DMI, cocaine, and substrate binding sites and perhaps reveal
additional structural features that are important for the func-
tion of the NET.
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